Autoimmune destruction of small intrahepatic bile ducts → cholestasis, pruritus, fatigue; AMA-positive in 95%.
Also known as: primary biliary cholangitis, PBC, primary biliary cirrhosis
Overview
Chronic autoimmune cholestatic liver disease characterized by progressive nonsuppurative destruction of small interlobular bile ducts, ultimately producing biliary cirrhosis. Renamed from 'primary biliary cirrhosis' to 'primary biliary cholangitis' in 2015 to reflect that most patients are diagnosed before cirrhosis.
Epidemiology
Predominantly affects middle-aged women (female:male 9:1); typical onset 40-60 years. Prevalence ~25-40 per 100,000. Often coexists with other autoimmune diseases (Sjögren, autoimmune thyroiditis, RA, celiac, scleroderma).
Try two board-style Primary Biliary Cholangitis questions
Real questions from the FirstPassPA bank, with the full explanation. Pick an answer — no signup, no email.
Question 1GastrointestinalMedium
A 62-year-old woman with primary biliary cholangitis has been taking ursodeoxycholic acid for 2 years, with normalization of her alkaline phosphatase and bilirubin. She has no cirrhosis. Which of the following is the most important long-term monitoring step?
ARepeat antimitochondrial antibody titers
BAnnual surveillance colonoscopy
CBone density (DEXA) screening
DSemiannual abdominal CT
EAnnual variceal screening endoscopy
Reveal answer & full explanation
Correct answer: C — Bone density (DEXA) screening
ARepeat antimitochondrial antibody titers
BAnnual surveillance colonoscopy
CBone density (DEXA) screening✓
DSemiannual abdominal CT
EAnnual variceal screening endoscopy
Why Bone density (DEXA) screening is correct
Chronic cholestasis in primary biliary cholangitis impairs absorption of vitamin D and calcium, so osteoporosis is a common complication in all patients regardless of disease stage or biochemical response
Guidelines recommend a baseline DEXA scan with periodic reassessment, plus calcium and vitamin D supplementation, as standard long-term care in primary biliary cholangitis
A good biochemical response to ursodeoxycholic acid lowers progression risk but does not remove the ongoing metabolic bone risk, so monitoring still matters
Why the others are wrong
Annual variceal screening endoscopy — Endoscopic variceal surveillance is indicated only once cirrhosis or portal hypertension is established, and this patient has neither (anchoring on chronic liver disease as automatically requiring endoscopy)
Repeat antimitochondrial antibody titers — Antimitochondrial antibody establishes the diagnosis, but its titer does not track disease activity, treatment response, or complications, so serial testing changes no management (confusing a diagnostic marker with a monitoring tool)
Semiannual abdominal CT — There is no role for routine surveillance CT; HCC surveillance, only once cirrhosis is present, is done with ultrasound every 6 months, not CT (confused with the HCC surveillance modality)
Annual surveillance colonoscopy — frequent surveillance colonoscopy is the rule in primary sclerosing cholangitis with coexisting inflammatory bowel disease, which makes it tempting in any cholestatic liver disease, but primary biliary cholangitis carries no such IBD association; she needs only age-appropriate colorectal cancer screening (confusing PBC with PSC)
Question 2GastrointestinalMedium
A 52-year-old woman presents with 6 months of progressive fatigue and intermittent nocturnal itching. She has a history of Sjögren syndrome. Examination shows excoriations on the forearms and mild hepatomegaly; there is no jaundice or ascites. Laboratory studies show alkaline phosphatase 410 U/L (3× ULN) and GGT 280 U/L, with AST 38 U/L and ALT 42 U/L and a normal total bilirubin. Antimitochondrial antibody is positive at 1:160, and IgM is elevated. Abdominal ultrasound shows no biliary dilation, and MRCP is normal. Which of the following is the most appropriate initial management?
ASeladelpar monotherapy
BCholestyramine resin therapy
CPrednisone immunosuppression
DOral ursodeoxycholic acid
EObeticholic acid monotherapy
Reveal answer & full explanation
Correct answer: D — Oral ursodeoxycholic acid
ASeladelpar monotherapy
BCholestyramine resin therapy
CPrednisone immunosuppression
DOral ursodeoxycholic acid✓
EObeticholic acid monotherapy
Why Oral ursodeoxycholic acid is correct
This is classic primary biliary cholangitis: a middle-aged woman with fatigue, pruritus, a cholestatic biochemistry (alkaline phosphatase and GGT disproportionately elevated relative to AST/ALT), positive AMA, and elevated IgM.
Per AASLD/EASL guidelines, ursodeoxycholic acid 13-15 mg/kg/day is first-line for ALL patients with PBC and is the only therapy proven to improve transplant-free survival. Biochemical response is reassessed at 12 months (e.g., Paris II criteria).
Why the others are wrong
Obeticholic acid monotherapy — obeticholic acid, an FXR agonist, was formerly a second-line option for inadequate response to or intolerance of UDCA, but it was withdrawn from the US market in 2025 after its confirmatory trial failed to verify clinical benefit and showed an excess of liver transplants and deaths in patients with early-stage disease; current second-line therapy is a PPAR agonist (elafibranor or seladelpar) added to UDCA, and no second-line agent is started up front.
Cholestyramine resin therapy — a bile acid sequestrant that treats the symptom of pruritus but does not alter disease progression; it must also be separated from UDCA by at least 4 hours and is adjunctive rather than initial disease-modifying therapy.
Prednisone immunosuppression — corticosteroids are the treatment for autoimmune hepatitis, which shows a hepatocellular (AST/ALT-predominant) pattern with ANA/ASMA and elevated IgG; it is not effective for PBC and adds osteoporosis risk in an already high-risk population.
Seladelpar monotherapy — seladelpar is a newer PPAR-delta agonist that can make the older drug seem outdated, but it is approved as second-line therapy, added to UDCA after an inadequate response or used alone only when UDCA cannot be tolerated; this treatment-naive patient starts with UDCA.
That's 2. Get 7,700+ more.
Unlock the full FirstPassPA bank: 7,700+ board-style questions, flashcards, and an AI tutor that explains every answer. Your 7-day free trial includes everything, and there's no credit card required.
You've read your 2 free diagnosis previews. Create your free account to unlock the full Primary Biliary Cholangitis (PBC) outline — plus all 514 diagnoses, 7,700+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.
Autoimmune injury (T-cell mediated with autoantibody markers — antimitochondrial antibodies (AMA) against the E2 subunit of pyruvate dehydrogenase) targets small bile duct epithelium, producing progressive ductopenia, cholestasis, and bile acid retention with secondary hepatocyte injury, fibrosis, and ultimately cirrhosis.
Clinical presentation
Symptoms
Often asymptomatic at diagnosis (incidental cholestatic LFT pattern in ~60%)
Fatigue (the most common symptom, often disabling)
Pruritus (often nocturnal, worsens before jaundice)
Hyperpigmentation, xanthelasmas, xanthomas (from prolonged cholestasis and hyperlipidemia)
Hepatomegaly, splenomegaly
Excoriations from scratching
Findings of associated autoimmune disease (Sjögren, thyroid, RA)
Late: jaundice, ascites, asterixis
Classic findings
Middle-aged woman with fatigue, pruritus, and isolated alkaline phosphatase elevation — check AMA.
Differential diagnosis
Primary sclerosing cholangitis — Cholestatic pattern with intrahepatic AND extrahepatic bile duct strictures on MRCP; strong IBD association; ANCA may be positive; AMA usually negative
2 of 3: (1) cholestatic biochemistry (elevated alkaline phosphatase ≥1.5× ULN >6 months), (2) AMA positive (≥1:40) or PBC-specific ANA, (3) liver biopsy showing nonsuppurative destructive cholangitis with bile duct injury. Biopsy not required if first two are met.
Labs
LFTs — cholestatic pattern: elevated alkaline phosphatase and GGT, normal-to-modestly elevated AST/ALT, normal bilirubin early
Antimitochondrial antibody (AMA) — positive in ~95%; highly specific
If AMA negative: AMA-negative PBC variants — anti-sp100, anti-gp210 (PBC-specific ANA patterns)
IgM (elevated), total IgG (less elevated than AIH)
Lipid panel (often markedly elevated cholesterol; not strongly atherogenic in PBC)
TSH (for coexistent autoimmune thyroiditis), celiac serology if symptoms
Fat-soluble vitamins (A, D, E, K) — deficiency in advanced cholestasis
Bone density (DEXA) — high osteoporosis risk
Imaging
Abdominal ultrasound — exclude biliary obstruction; nonspecific for PBC
MRCP — typically normal in PBC (distinguishes from PSC, which shows beading)
Treatment
First-line
Ursodeoxycholic acid (UDCA) 13-15 mg/kg/day in divided doses — first-line for all PBC patients; improves transplant-free survival
Assess biochemical response at 12 months: e.g., Paris II criteria (ALP and AST ≤1.5× ULN with normal bilirubin); inadequate response → add second-line therapy
Second-line / adjunct
PPAR agonist for incomplete UDCA response (added to UDCA) or UDCA intolerance (alone): elafibranor 80 mg daily or seladelpar 10 mg daily (FDA accelerated approval 2024); not recommended in decompensated cirrhosis. Obeticholic acid (FXR agonist) was withdrawn from the US market in 2025
UDCA is the only therapy proven to improve transplant-free survival in PBC — start in all patients.
Second-line therapy for inadequate UDCA response is now a PPAR agonist (elafibranor or seladelpar) added to UDCA; obeticholic acid was withdrawn from the US market in 2025 after its confirmatory trial failed to show clinical benefit.
PBC has the highest osteoporosis risk of any chronic liver disease — DEXA every 2 years, calcium and vitamin D for all.
References
AASLD 2018 — AASLD Practice Guidance: Primary Biliary Cholangitis (Lindor et al., Hepatology 2019)
EASL 2017 — EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis (J Hepatol 2017)
AASLD 2021 — Primary biliary cholangitis: 2021 practice guidance update from the American Association for the Study of Liver Diseases (Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M; Hepatology 2022;75:1012-1013)
FDA 2024-2025 — US FDA: accelerated approvals of elafibranor (Iqirvo) and seladelpar (Livdelzi) for PBC (prescribing information, 2024); withdrawal of approval of obeticholic acid (Ocaliva) NDA 207999 (Federal Register 2025;90:52976-52977)
Practice Gastrointestinal questions on FirstPassPA
Turn this outline into retention. 7,700+ board-style questions with an AI tutor that explains every answer — free to start, no card required.
Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.